REGN-24493 Market Summary

Key Factors Driving REGN-24493 Growth

1. First-in-Class TSHR Antagonist Targeting the Primary Driver of Graves' Disease

REGN24493 directly binds to and blocks the thyroid-stimulating hormone receptor (TSHR), preventing activation by pathogenic thyroid-stimulating autoantibodies (TSAbs), which are the principal cause of Graves' disease and a key driver of TED. Unlike current antithyroid drugs that inhibit thyroid hormone synthesis, REGN24493 is designed to intervene at the upstream autoimmune mechanism, potentially offering a disease-modifying approach for both thyroid dysfunction and orbital disease. Regeneron highlighted this differentiated mechanism in its ENDO 2026 scientific presentations.

2. Strong Preclinical Data Demonstrating Potent TSHR Blockade

Regeneron presented in vitro and in vivo data at ENDO 2026 showing that REGN24493 effectively binds TSHR and blocks downstream signaling induced by disease-causing autoantibodies. In mouse models of Graves' disease and TED, the antibody reduced hyperthyroidism and improved proptosis, providing proof-of-concept that TSHR antagonism can address both endocrine and ophthalmic manifestations of disease. These findings substantially strengthen confidence in the program before clinical development.

3. Opportunity to Address Significant Unmet Need in Graves' Disease and TED

Current Graves' disease therapies—including methimazole, radioactive iodine, and thyroidectomy—primarily control thyroid hormone production but do not directly target the autoimmune process, and many patients experience relapse or permanent hypothyroidism. Likewise, treatment options for TED remain limited despite recent advances. A biologic that directly blocks TSHR could potentially provide a more targeted and durable therapeutic option across both conditions, creating a meaningful commercial opportunity if clinical efficacy is confirmed.

4. Potential to Treat Two Closely Related Autoimmune Diseases with One Therapy

TSHR is the central pathogenic receptor in both Graves' disease and Thyroid Eye Disease, allowing REGN24493 to be developed across two indications using a single mechanism of action. This dual-indication strategy could substantially expand the addressable patient population while enabling efficient lifecycle management. The preclinical studies demonstrating improvements in both thyroid function and orbital disease support this broader development strategy.

5. Backing from Regeneron's Antibody Development Platform

Regeneron has an established track record of discovering and commercializing monoclonal antibodies using its proprietary antibody platforms. The company's extensive biologics manufacturing capabilities, translational research expertise, and regulatory experience improve the likelihood of efficient clinical development and global commercialization if REGN24493 advances successfully. Continued inclusion of the program in Regeneron's endocrine and rare disease pipeline presentations indicates ongoing strategic investment.

REGN-24493 Recent Developments

In June 2026, Regeneron Pharmaceuticals, Inc. announced that new clinical data and research from its metabolic disease, ophthalmology and rare disease pipelines will be presented at two major medical meetings. These include the American Diabetes Association (ADA) 86th Scientific Sessions, and the Endocrine Society Annual Meeting (ENDO 2026).

“REGN-24493 Sales Forecast, and Market Size Analysis – 2034” report provides comprehensive insights of REGN-24493 for potential indication like Graves ophthalmopathy and Graves’ disease in the 7MM. A detailed picture of REGN-24493’s existing usage in anticipated entry and performance in potential indications in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2020 –2034 is provided in this report along with a detailed description of the REGN-24493 for potential indications. The REGN-24493 market report provides insights about REGN-24493’s sales forecast, mechanism of action (MoA), dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of historical and current REGN-24493 performance, future market assessments inclusive of the REGN-24493 market forecast analysis for potential indications in the 7MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in respective indications. It also provides analysis of REGN-24493 sales forecasts, along with factors driving its market.

REGN-24493 Drug Summary

REGN-24493 is an investigational fully human monoclonal antibody being developed by Regeneron Pharmaceuticals for the treatment of Graves’ disease (GD) and thyroid eye disease (TED). The antibody is designed to selectively antagonize the thyroid-stimulating hormone receptor (TSHR), the principal autoantigen driving both disorders, by binding to TSHR and preventing activation by pathogenic thyroid-stimulating autoantibodies (TSAbs). This targeted mechanism aims to inhibit the downstream signaling responsible for excessive thyroid hormone production, orbital fibroblast activation, inflammation, and tissue expansion, thereby addressing the underlying cause of GD and TED rather than merely controlling symptoms. Preclinical studies have demonstrated that REGN24493 exhibits high-affinity binding to human TSHR, effectively blocks TSAb-mediated receptor activation across multiple patient-derived antibodies, and suppresses disease-relevant signaling pathways. As of 2026, REGN24493 remains in preclinical development, with supporting data presented at ENDO 2026 highlighting its potential as a first-in-class TSHR antagonist, and it has not yet entered human clinical trials or received regulatory approval. The report provides REGN-24493’s sales, growth barriers and drivers, post usage and approvals in multiple indications.

Scope of the REGN-24493 Market Report

The report provides insights into:

• A comprehensive product overview including the REGN-24493 MoA, description, dosage and administration, research and development activities in potential indication like Graves ophthalmopathy and Graves’ disease.
• Elaborated details on REGN-24493 regulatory milestones and other development activities have been provided in REGN-24493 market report.
• The report also highlights REGN-24493‘s cost estimates and regional variations, reported and estimated sales performance, research and development activities in potential indications across the United States, Europe, and Japan.
• The REGN-24493 market report also covers the patents information, generic entry and impact on cost cut.
• The REGN-24493 market report contains current and forecasted REGN-24493 sales for potential indications till 2034.
• Comprehensive coverage of the late-stage emerging therapies for respective indications.
• The REGN-24493 market report also features the SWOT analysis with analyst views for REGN-24493 in potential indications.

Methodology

The REGN-24493 market report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

REGN-24493 Analytical Perspective by DelveInsight

• In-depth REGN-24493 Market Assessment

This REGN-24493 sales market forecast report provides a detailed market assessment of REGN-24493 for potential indication like Graves ophthalmopathy and Graves’ disease in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides current and forecasted REGN-24493 sales data uptil 2034.

• REGN-24493 Clinical Assessment

The REGN-24493 market report provides the clinical trials information of REGN-24493 for potential indications covering trial interventions, trial conditions, trial status, start and completion dates.

REGN-24493 Competitive Landscape

The report provides Insights on competitors and marketed products within the domain, along with a summary of emerging products and their respective launch dates, posing significant competition in the market.

REGN-24493 Market Potential & Revenue Forecast

• Projected market size for the REGN-24493 and its key indications
• Estimated REGN-24493 sales potential (REGN-24493 peak sales forecasts)
• REGN-24493 Pricing strategies and reimbursement landscape

REGN-24493 Competitive Intelligence

• Number of competing drugs in development (pipeline analysis)
• REGN-24493 Market positioning compared to existing treatments
• REGN-24493 Strengths & weaknesses relative to competitors

REGN-24493 Regulatory & Commercial Milestones

• REGN-24493 Key regulatory approvals & expected launch timelines
• Commercial partnerships, licensing deals, and M&A activity

REGN-24493 Clinical Differentiation

• REGN-24493 Efficacy & safety advantages over existing drugs
• REGN-24493 Unique selling points

REGN-24493 Market Report Highlights

• In the coming years, the REGN-24493 market scenario is set to change due to strong adoption, increased prescriptions and broader uptake in multiple immunological indications; which would expand the size of the market.
• The REGN-24493 companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence REGN-24493’s dominance.
• Other emerging products for Graves ophthalmopathy and Graves’ disease are expected to give tough market competition to REGN-24493 and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of REGN-24493 in potential indications.
• Analyse REGN-24493 cost, pricing trends and market positioning to support strategic decision-making in the immunology landscape.
• Our in-depth analysis of the forecasted REGN-24493 sales data uptil 2034 will support the clients in decision-making process regarding their therapeutic portfolio by identifying the overall scenario of REGN-24493 in potential indications.

Key Questions

• What is the class of therapy, route of administration and mechanism of action of REGN-24493? How strong is REGN-24493’s clinical and commercial performance?
• What is REGN-24493’s clinical trial status in each individual indications such as Graves ophthalmopathy and Graves’ disease and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the REGN-24493 Manufacturers?
• What are the key designations that have been granted to REGN-24493 for potential indications? How are they going to impact REGN-24493’s penetration in various geographies?
• What is the current and forecasted REGN-24493 market scenario for potential indications? What are the key assumptions behind the forecast?
• What are the current and forecasted sales of REGN-24493 in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
• What are the other emerging products available and how are these giving competition to REGN-24493 for potential indications?
• Which are the late-stage emerging therapies under development for the treatment of potential indications?
• How cost-effective is REGN-24493? What is the duration of therapy and what are the geographical variations in cost per patient?